ADVERTISEMENT

ADA 2021 — Finerenone beneficial in patients with T2D and CKD, irrespective of SGLT2i use

Pavankumar Kamat   |   Conference Report   |   30 June 2021
ADVERTISEMENT

Takeaway

  • Finerenone was associated with improved renal and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), irrespective of sodium/glucose cotransporter-2 inhibitor (SGLT2i) use at baseline.

Why this matters

  • Patients with CKD and T2D often have an unmet treatment need despite SGLT2i treatment.

Study...

          

March Challenge

Ends in 4d
left
right

Topic Challenges

left
right